These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 2502062

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Pharmacokinetics of monoclonally-purified and recombinant factor VIII in patients with severe von Willebrand disease.
    Morfini M, Mannucci PM, Tenconi PM, Longo G, Mazzucconi MG, Rodeghiero F, Ciavarella N, De Rosa V, Arter A.
    Thromb Haemost; 1993 Aug 02; 70(2):270-2. PubMed ID: 8236134
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Plasma exchange donation of cryoprecipitate after DDAVP stimulation: an alternative source of factor VIII.
    McLeod BC, Scott JP.
    Prog Clin Biol Res; 1990 Aug 02; 324():189-98. PubMed ID: 2106687
    [Abstract] [Full Text] [Related]

  • 26. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P, Gensana M, Fernández J, Massot M, Biescas H, Darling A, Jorquera JI, Vericat F.
    Sangre (Barc); 1996 Apr 02; 41(2):131-6. PubMed ID: 9045353
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate.
    Allersma DP, Smid WM, van der Does JA, van der Meer J, Briët E.
    Thromb Haemost; 1996 Feb 02; 75(2):261-6. PubMed ID: 8815573
    [Abstract] [Full Text] [Related]

  • 29. Monoclonal antibodies against the human factor VIII von Willebrand molecule: characterization and potential for screening of von Willebrand patients.
    Avner P, Arnaud D, Sultan Y, Maisonneuve P, Jeanneau C.
    Dev Biol Stand; 1984 Feb 02; 57():69-76. PubMed ID: 6084622
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R, Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D.
    Thromb Haemost; 1994 May 02; 71(5):544-7. PubMed ID: 8091377
    [Abstract] [Full Text] [Related]

  • 34. Biological activity of von Willebrand factor during the manufacture of therapeutic factor VIII concentrates as determined by the collagen-binding assay.
    Ramasamy I, Farrugia A, Tran E, Anastasius V, Charnock A.
    Biologicals; 1998 Jun 02; 26(2):155-66. PubMed ID: 9811523
    [Abstract] [Full Text] [Related]

  • 35. Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
    Berntorp E.
    Haematologica; 2003 Jun 02; 88(6):EREP03. PubMed ID: 12826529
    [Abstract] [Full Text] [Related]

  • 36. The course of preexistent immune abnormalities in HIV negative haemophiliacs treated for two years with a monoclonal purified factor VIII concentrate.
    Smid WM, van der Meer J, Smit JW, Halie MR.
    Thromb Haemost; 1993 Apr 01; 69(4):306-10. PubMed ID: 8388579
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.